Skip to main content

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting · Not applicable · NCT05677100

Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure, With Decompensation, Heart Failure, Congestive

At a glance

Research payments reported, 2025
$1.8M
U.S. investigators named
51
Sites paid
45
Planned or actual enrollment
320

About the trial

Sponsor
Procyrion
Tested
Aortix System (device)
Dates
Started 2023-08-23; completion 2028-08
Results posted
Not yet

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

From ClinicalTrials.gov, last updated 2026-08-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Procyrion, Inc. reported $1.8M in research payments for this study in 2025 (48 payments).

Products named: Aortix System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.